Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: Coexpression and correlation with clinicopathologic parameters

Experimental and Molecular Pathology

Volumn 79, Issue 1, 2005, Pages 42-50

  Sirotkovic Skerlev, Maja ^a   Krizanac, Simun ^a   Kapitanovic, Sanja ^b   Husnjak, Koraljka ^b   Unusic, Josip ^a   Pavelic, Kresimir ^b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Breast lesions; c myc; erbB 2; Gene product expression; nm23 H1; p53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENE PRODUCT; MUTANT PROTEIN; MYC PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE A; PROTEIN P53;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BENIGN TUMOR; BREAST CARCINOMA; CANCER SIZE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PHENOTYPE;

ADULT; BREAST DISEASES; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; NUCLEOSIDE-DIPHOSPHATE KINASE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 22144481597     PISSN: 00144800     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexmp.2005.02.004     Document Type: Article

References (44)

1. B. Belev, I. Aleric, D. Vrbanec, M. Petrovecki, J. Unusic, and J. Jakic-Razumovic Nm23 gene product expression in invasive breast cancer-immunohistochemical analysis and clinicopathological correlation Acta Oncol. 41 2002 355 361
2. J. Bergh, T. Norberg, S. Sjoegren, A. Lindgren, and L. Homberg Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy Nat. Med. 1 1995 1029 1034
3. P. Bertheau, S.M. Steinberg, and M.J. Merino C-erbB-2, p53 and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation Hum. Pathol. 29 1998 323 329
4. S. Bianchi, M. Paglierani, G. Zampi, G. Cardona, L. Cataliotti, R. Bonardi, and S. Ciatto Prognostic significance of c-erbB-2 expression in node negative breast cancer Br. J. Cancer 67 1993 625 629
5. H.J. Bloom, and W.W. Richardson Histological grading and prognosing in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years Br. J. Cancer 11 1957 359 377
6. A. Borg, B. Baldetorp, M. Fernoe, H. Olsson, and H. Sigurdsson c-myc amplification is an independent prognostic factor in postmenopausal breast cancer Int. J. Cancer 51 1992 687 691
7. A.L. Borresen-Dale TP53 and breast cancer Hum. Mutat. 21 2003 292 300
8. G. Cattoretti, F. Rilke, S. Andreola, L. D'Amato, and D. Delia p53 expression in breast cancer Int. J. Cancer 41 1988 178 183
9. C. Charpin, C. Bouvier, S. Garcia, F. Martini, L. Andrac, M.N. Lavaut, and C. Allasia Automated and quantitative immunocytochemical assays of Nm23/NDPK protein in breast carcinomas Int. J. Cancer (Pred. Oncol.) 74 1997 416 420
10. K.M. Dameron, O.V. Volpert, M.A. Tainsky, and N. Bouck Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 Science 265 1994 1582 1584
11. A.M. Davidoff, P.A. Humphrey, J.D. Iglehart, and J.R. Marks Genetic basis for p53 overexpression in human breast cancer Proc. Natl. Acad. Sci. U. S. A. 88 1991 5006 5010
12. S.L. Deming, S.J. Nass, R.B. Dickson, and B.J. Trock C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance Br. J. Cancer 83 2000 1688 1695
13. A. Duenas-Gonzalez, M.M. Abad-Hernandez, J. Garcia-Mata, J.I. Paz-Bouza, J.J. Cruz-Hernandez, and R. Gonzalez-Sermiento Analysis of nm23-H1 expression in breast cancer. Correlation with p53 expression and clinicopathologic findings Cancer Lett. 101 1996 137 142
14. Y. Emi, K. Kitamura, Y. Shikada, Y. Kakeji, I. Takahashi, and S. Tsutsui Metastatic breast cancer with HER2/neu-positive cells tend to have a morbid prognosis Surgery 131 2002 S217 S221
15. G.I. Evan, G.K. Lewis, G. Ramsay, and M. Bishop Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product Mol. Cell. Biol. 5 1985 3610 3616
16. L.M. Facchini, and L.Z. Penn The molecular role of myc in growth and transformation: recent discoveries lead to new insights FASEB J. 12 1998 633 651
17. J.V. Gannon, R. Greaves, R. Iggo, and D.P. Lan Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form EMBO J. 9 1990 1595 1602
18. M.S. Greenblatt, W.P. Bennett, M. Hollstein, and C.C. Harris Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res. 54 1994 4855 4878
19. W.J. Gullick, S.B. Love, C. Wright, D.M. Barnes, B. Gusterson, A.L. Harris, and D.G. Altman C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes Br. J. Cancer 63 1991 434 438
20. B.A. Gusterson, L.G. Machin, W.J. Gullick, N.M. Gibbs, T.J. Powles, C. Elliott, S. Ashley, P. Monaghan, and S. Harrison c-erbB-2 expression in benign and malignant breast disease Br. J. Cancer 58 1988 453 457
21. C. Hennessy, J.A. Henry, F.E. May, B.R. Westley, B. Angus, and T.W. Lennard Expression of the anti-metastatic gene nm23 in human breast cancer: an association with good prognosis J. Nat. Cancer Inst. 83 1991 281 285
22. K.B. Horwitz, and W.L. McGuire Progesterone and progesterone receptors in experimental breast cancer Cancer Res. 37 1977 1733 1738
23. J. Jakic-Razumovic, M. Petrovecki, B. Uzerevic, and S. Gamulin Mutual predictive value of c-erbB-2 overexpression and various prognostic factors in ductal invasive breast carcinoma Tumori 86 2000 30 36
24. J.D. Kantor, B. McCormick, P.S. Steeg, and B.R. Zetter Inhibition of cell motility after nm23 transfection of human and murine tumor cells Cancer Res. 53 1993 1971 1973
25. HER-2/neu correlates with the stage of disease and survival in colorectal cancer Gastroenterology 112 1997 1103 1113
26. J.C. Keen, and N.E. Davidson The biology of breast carcinoma Cancer 97 2003 825 833
27. D. Korkolis, A. Ardavanis, J. Yotis, A. Kyroudi, V. Gorgoulis, and C. Kittas HER-2/neu overexpression in breast cancer: an immunohistological study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D Anticancer Res. 21 2001 2207 2212
28. A. Leone, U. Flatow, K. VanHoutte, and P.S. Steeg Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potential, colonization and enzymatic activity Oncogene 8 1993 2325 2333
29. D.J. Liao, and R.B. Dickson c-Myc in breast cancer Endocr. Relat. Cancer 7 2000 143 164
30. R. Millikan, B. Hulka, A. Thor, Y. Zhang, S. Edgerton, X. Zhang, H. Pei, M. He, L. Wold, L.J. Melton, D. Ballard, K. Conway, and E.T. Liu p53 mutations in benign breast tissue J. Clin. Oncol. 13 1995 2293 2300
31. E.C. Mommers, P.J. van Diest, A.M. Leonhart, C.J. Meijer, and J.P. Baak Expression of proliferation and apoptosis-related proteins in usual ductal hyperplasia of the breast Hum. Pathol. 29 1998 1539 1545
32. N. Quénel, J. Wafflart, F. Bonichon, I. de Mascarel, M. Trojani, M. Durand, A. Avril, and J.M. Coindre The prognostic value of c-erbB2 in primary breast carcinomas: a study of 942 cases Breast Cancer Res. Treat. 35 1995 283 291
33. F. Revillon, J. Bonneterre, and J.P. Peyrat ErbB-2 oncogene in human breast cancer and its clinical significance Eur. J. Cancer 34 1998 791 808
34. R.C. Richie, and J.O. Swanson Breast cancer: a review of the literature J. Insur. Med. 35 2003 85 101
35. P.P. Rosen, M.L. Lesser, C.D. Arroyo, M. Cranor, P. Borgen, and L. Norton Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma: a study of epidemiologic risk factors, histologic features, and prognosis Cancer 75 1995 1320 1326
36. A.J. Sasco, R. Kaaks, and R.E. Little Breast cancer: occurrence, risk factors and hormone metabolism Expert. Rev. Anticancer Ther. 3 2003 546 562
37. A. Sawan, I. Llascu, M. Veron, J.J. Anderson, C. Wright, C.H.W. Horne, and B. Angus NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: an immunohistochemical study J. Pathol. 172 1994 27 34
38. C.M. Schlotter, U. Vogt, U. Bosse, B. Mersch, and K. Wassmann C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer Breast Cancer Res. 5 2003 R30 R36
39. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, W.J. Levin, S.G. Stuart, J. Udove, A. Ullrich, and M.F. Press Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
40. R. Spaventi, E. Kamenjicki, N. Pecina, S. Grazio, S. Grazio, J. Pavelic, B. Kusic, D. Cvrtila, Z. Danilovic, S. Spaventi, K. Pavelic, J. Gluckman, and Z.P. Pavelic Immunohistochemical detection of TGF-α, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: a concomitant expression? In vivo 8 1994 183 190
41. R. Spaventi, L. Pecur, K. Pavelic, Z.P. Pavelic, S. Spaventi, and P.J. Stambrook Human Tumor Bank in Croatia: a possible model for small bank as a part of the future European Tumor Bank Network Eur. J. Cancer 30A 1994 419
42. P.S. Steeg, G. Bevilacqua, L. Kopper, U.P. Thorgeirsson, J.E. Talmadge, L.A. Liotta, and M.E. Sobel Evidence for novel gene associated with low tumor metastatic potential J. Natl. Cancer Inst. 80 1988 200 204
43. M. Younes, R.M. Lebovitz, K.E. Bommer, P.T. Cagle, D. Morton, S. Khan, and R. Laucirica p53 accumulation in benign breast biopsy specimens Hum. Pathol. 26 1995 155 158
44. K. Zimmerman, and F.W. Alt Expression and function of myc family genes Crit. Rev. Oncog. 2 1990 75 95